Hims & Hers Health (HIMS) stock declined about 2% yesterday. The fall came after the U.S. Food and Drug Administration (FDA) ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

According to the FDA, they have not received official approval, and no comprehensive safety data has been submitted for them.

Hims, Keeps and other companies advertise topical finasteride with limited disclosures of side effects.

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want ...

We recently published a list of 10 Best Telehealth Stocks to Buy Now. In this article, we are going to take a look at where ...

Hims & Hers has shown explosive growth, with potential revenue of $2.5B in FY25, trading at a low 2.4x FY25 sales. Learn more ...

Zacks Equity Research shares Hims & Hers Health HIMS as the Bull of the Day and AST SpaceMobile ASTS as the Bear of the D ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

BofA notes that the Food and Drug Administration issued an alert on the potential risks associated with compounded topical finasteride products ...

Since April 2020, the S&P 500 has delivered a total return of 92.9%. But one standout stock has nearly doubled the market - ...

Hims & Hers' Chief Operating Officer Melissa Baird will transition into an advisory role with the telehealth company in the coming months.